MicroPort CRM Announces First Implants of EnoTM and TeoTM, World’s Smallest 1.5T & 3T MRI Conditional Pacemakers*

Clamart, France – January 23rd, 2019 – MicroPort® CRM (a business unit of MicroPort Scientific Corporation), is pleased to announce the first implants of its new pacemaker families Eno™ and Teo™.

The first worldwide Eno™ implant took place in Clinique La Source, Lausanne, Switzerland. “We see how elderly patients currently need imaging, and it’s really nice to have 3T MR-conditional devices” commented Dr Reverdin, who performed the implantation. “The product features automatic MRI programming which is practical for patients and physicians, and will potentially reduce the costs generated by in-hospital workflows.”

The first Teo™ implants were performed by Dr. Schouwink at Katharinen-hospital, Unna, Germany. “The fact that the pacemaker is so small really has many advantages,” said Dr Georg Nölker, head of the cardiology department at Katharinen-Hospital. “Patients who are younger and thin will particularly tolerate the therapy better – psychologically and physically.”

All models of these new pacemaker families feature AutoMRITM technology allowing patients implanted with compatible leads to undergo MRI (Magnetic Resonance Imaging) scans in either 1.5 Tesla or 3 Tesla machines. AutoMRITM automatically switches in and out of MRI mode upon detection of the MR field, ensuring appropriate pacemaker operation during the scan and allowing patients to benefit from optimal pacing settings right up to and just after the scan.

The new pacemaker portfolio also features:

  • Phi IntelligenceTM : a permanent adaptive pacing strategy that responds to all levels of patient activity, day and night, evolving and learning with the patient’s conditions in order to mimic the natural way the heart works, minimizing artificial intervention.
  • AF Risk ManagementTM : a unique combination of features that helps physicians to accurately detect Atrial Fibrillation (AF), minimize ventricular pacing and screen for sleep apnea so as to protect patients from developing AF.
  • Preset FitTM : a set of capabilities including precision programming calibrated through clinical experience and designed to facilitate the implant procedure and device follow up.

*Transvenous cardiac pacing systems

About MicroPort CRM

Pioneering physiological therapies in cardiac rhythm management. Driven by our expert R&D teams and state-of-the-art manufacturing facilities across the globe, MicroPort CRM conceives, designs and develops solutions for the management of cardiac rhythm disorders and heart failure. Headquartered in Paris, our precise technologies are manufactured in France, Italy, the Dominican Republic; and for the Chinese market, in China. MicroPort CRM is part of MicroPort® Scientific Corporation.

 For more information visit www.crm.microport.com

About MicroPort®

MicroPort Scientific Corporation (the “Group”) is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, anticipate”, “project”, “estimate”, “predict”, “is confident”, “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®‘s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.




All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

Exemplary message

By continuing to browse this website you confirm that you are a healthcare professional.